نتایج جستجو برای: reteplase

تعداد نتایج: 161  

Journal: :European heart journal 2000
E M Antman C M Gibson J A de Lemos R P Giugliano C H McCabe P Coussement I Menown C A Nienaber T C Rehders M J Frey R Van der Wieken D Andresen J Scherer K Anderson F Van de Werf E Braunwald

Aims Abciximab has previously been shown to enhance thrombolysis and improve myocardial perfusion when combined with reduced doses of alteplase. The purpose of the reteplase phase of TIMI 14 was to evaluate the effects of abciximab when used in combination with a reduced dose of reteplase for ST-elevation myocardial infarction. Methods and Results Patients (n=299) with ST-elevation myocardial i...

Journal: :Lancet 2001
E J Topol

BACKGROUND Plasminogen activator therapy for acute myocardial infarction is limited by lack of achievement of early, complete, and sustained reperfusion in a substantial proportion of patients. Many phase II trials have supported the potential of combined fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition for improving reperfusion. We did a randomised, open-label trial to compar...

Journal: :Circulation 1999
M Moser T Nordt K Peter J Ruef B Kohler M Schmittner R Smalling W Kübler C Bode

BACKGROUND Changes in platelet aggregation (PA) and platelet surface receptor expression induced by thrombolytic therapy for acute myocardial infarction may influence the rate of initial reperfusion and early reocclusion. METHODS AND RESULTS In the RAPID-1 (Reteplase Angiographic Phase II International Dose-finding study), RAPID-2 (Reteplase vs Alteplase Patency Investigation During myocardia...

Journal: :Journal of biochemical and biophysical methods 2006
Zhigang Guo Feng Bi Yanchun Tang Jing Zhang Dawen Yuan Zhinan Xia Jian-Ning Liu

The work was to explore the feasibility of protein affinity purification using ligand isolated from phage library. Reteplase was used as the model protein and a humanized semi-synthetic single chain fragment variable phage library as the source of ligand. After four rounds of biopanning, reteplase-specific phage clones were greatly enriched. The scFv gene from the best phage clone was inserted ...

2011
Fatemeh Shafiee Fatemeh Moazen Mahammad Rabbani Hamid Mir Mohammad Sadeghi

BACKGROUND Reteplase is a mutant version of t-PA (tissue plasminogen activator) with prolonged half-life. In the present study, E. coli Top 10 bacteria were utilized in the production of reteplase, which is the nonglycosylated active domain of t-PA. Reteplase gene was ligated into pBAD/gIII plasmid which, allows secretion of this protein in periplasmic space. It would allow the correct formatio...

Journal: :Avicenna journal of medical biotechnology 2016
Mehrnoosh Fathi-Roudsari Asal Akhavian-Tehrani Nader Maghsoudi

BACKGROUND Escherichia coli (E. coli) is the most extensively used host for the production of recombinant proteins. However, most of the eukaryotic proteins are typically obtained as insoluble, misfolded inclusion bodies that need solubilization and refolding. Reteplase as a highly disulfide-bonded recombinant protein is an example of difficult to express protein in E. coli. METHODS In this s...

2016
PAUL A. GURBEL ANDREW R. SHUSTOV

Objectives. We sought to compare platelet characteristics after reteplase and alteplase therapy in the setting of the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO)-III trial. Background. Platelet function may be impaired during thrombolysis in patients with an acute myocardial infarction. The effects of reteplase and alteplase on platelet aggregation and major surface anti...

Journal: :The New England journal of medicine 1997

BACKGROUND Reteplase (recombinant plasminogen activator), a mutant of alteplase tissue plasminogen activator, has a longer half-life than its parent molecule and produced superior angiographic results in pilot studies of acute myocardial infarction. In this large clinical trial, we compared the efficacy and safety of these two thrombolytic agents. METHODS A total of 15,059 patients from 807 h...

Journal: :European heart journal 1997
C Bode K Peter M Moser R W Smalling W D Weaver

Thrombolysis has become an accepted form of therapy for acute myocardial infarction. As demonstrated in the Global Utilization of Streptokinase and t-PA for Occluded Arteries trial, early, complete and sustained patency of the infarct-related coronary artery is correlated with reduced mortality. However, current thrombolytic regimens are able to achieve such patency within 90 min in only 81% of...

Journal: :journal of paramedical sciences 0
fatemeh shafiee department of pharmaceutical biotechnology and isfahan pharmaceutical sciences research center, school of pharmacy, isfahan university of medical sciences, isfahan, iran fatemeh moazen department of pharmaceutical biotechnology and isfahan pharmaceutical sciences research center, school of pharmacy, isfahan university of medical sciences, isfahan, iran mahammad rabbani department of pharmaceutical biotechnology and isfahan pharmaceutical sciences research center, school of pharmacy, isfahan university of medical sciences, isfahan, iran hamid mir mohammad sadeghi department of pharmaceutical biotechnology and isfahan pharmaceutical sciences research center, school of pharmacy, isfahan university of medical sciences, isfahan, iran

reteplase is a part of tissue plasminogen activator (t-pa) used for theremoval of thrombi in blood vessels. in the present study we express the reteplase genein escherichia coli top10 and then its thrombolytic activity was measured. the recombinant plasmid pbadgiiia was transformed into the competent escherichia coli top10 and then transformed bacteria was seeded into bioreactor containing 1.5 ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید